What Biosimilar Launch Timing Actually Depends On in a CIP-Heavy Patent Landscape Biosimilar launch timing in a CIP-heavy patent landscape is determined by three factors operating in sequence: the settlement negotiations between the innovator and the biosimilar developer, the results of any litigation on patents the parties cannot resolve by agreement, and the regulatory exclusivity periods 12 years for reference biologics under the BPCIA that run independently of patent status
The study's methodology was designed to induce PEM in ME/CFS patients, allowing for an examination of the metabolic differences in plasma between patients and controls, particularly in energy metabolism
By submitting, you agree to receive appointment reminders and promotional emails
others were excluded due to translation limitations
62,63 Intestinal FXR mediates suppression of lipid absorption, while hepatic FXR inhibits lipid synthesis
This hormonal imbalance creates an environment that stimulates thecal androgen production without supporting the follicle maturation needed for normal ovulation